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Abstract 
 
Over the last century, scientists have embraced the idea of mobilising anti-tumour 
immune responses in patients with cancer. In the last decade we have seen the rebirth 
of cancer immunotherapy and its validation in a series of high profile clinical trials 
following the discovery of several immune-regulatory receptors. Recent studies point 
towards the tumour mutational load and resulting neoantigen burden as being crucial 
to tumour cell recognition by the immune system, highlighting a potentially targetable 
Achilles heel in cancer. In this review we explore the key mechanisms that underpin 
the recognition of cancerous cells by the immune system and discuss how we may 
advance immunotherapeutic strategies to target the cancer mutanome in order to 
stimulate tumour-specific immune responses, ultimately, to improve the clinical 
outcome for patients with cancer.  
 
Introduction 
 
The concept of cancer immunotherapy originates from observations made by William 
Coley in the late 19th Century (Figure 1).1 He documented tumour regression in patients 
with acute bacterial infections, and proceeded to test bacterial extracts, referred to as 
‘Coley’s toxins’, in patients with bone and soft tissue sarcomas. Despite the 
encouraging results reported by Coley, a lack of understanding with regards to the 
mechanism of action of these toxins in conjunction with the emergence of radiotherapy 
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as a treatment modality led to a decline in the use of Coley’s toxin.  Subsequent 
research in cancer immunology however, led to the development and evaluation of 
several novel immune-therapeutics, namely interleukin-2, interferon gamma (IFNγ), 
tumour necrosis factor and numerous cancer vaccines.  
 
Whilst several of these therapeutic strategies produced interesting results in patients 
with solid cancers, the clinical responses were often short-lived and limited to a small 
fraction of treated patients. The advent of T cell checkpoint molecule inhibitors has 
revolutionised the therapeutic landscape for patients, enthusing scientists globally to 
better understand the basic mechanisms that underpin the recognition of cancerous 
cells by the endogenous immune system. It is evident from published data to date that 
the tumour mutational load and the consequent generation of neoantigens are one of 
the important components of an effective anti-tumoural immune response, 
representing the Achilles heel of cancerous cells. Immunotherapeutic strategies, for 
example cancer vaccines or adoptive cellular therapy targeted towards tumour 
neoantigens in combination with checkpoint molecule inhibitors provide a means of 
delivering a clinically valuable anti-tumoural effect through enhancement and 
activation of tumour specific immune responses.  
 
Clinical successes of immune checkpoint therapies 
 
A significant amount of basic and translational research has been directed towards 
gaining a better understanding of how the immune response to cancer is regulated. A 
key inflection point in the history of cancer immunotherapy was the discovery of an 
immune receptor expressed at high levels by in vitro activated T cells, cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4).2 Whilst its function was elusive at first, a 
number of experiments demonstrated the role of CTLA-4 as a co-inhibitory receptor, 
responsible for the downregulation of T cell activity.  In the mid 1990s several groups 
proposed that CTLA-4 would act as an immune checkpoint restricting the activity of 
tumour reactive T cells.3-9 Inhibition of T cell proliferation and IL-2 secretion was 
mediated following CTLA-4 activation and subsequent data demonstrated the effective 
rejection of tumours in murine models of cancer using antibodies against CTLA-4.4,5 
Further evaluation of mechanism of action has suggested that the antibodies can act 
both by directly blocking inhibitory signals of regulatory T cells and by driving Fcγ 
receptor mediated depletion of tumour infiltrating regulatory T cells expressing higher 
levels of CTLA-4 than effector T cells.10-13  
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These key studies gave rise to the concept of immune regulation of T cells involved in 
anti-tumoural immunity, mediated by CTLA-4, leading to the clinical development of 
antibodies targeting CTLA-4. Ipilimumab, a fully humanised monoclonal antibody to 
CTLA-4 was demonstrated to deliver durable responses in patients with advanced 
melanoma in several clinical trials, leading to its approval by the US Food and Drug 
Administration (FDA) for the treatment of metastatic melanoma in 2011. 
 
The discovery of a second T cell co-inhibitory molecule of the B7 family, programmed 
death receptor 1 (PD-1)14 and its ligand programmed death receptor ligand 1 (PD-L1)15 
was later followed by data showing that blockade of the PD-1/PD-L1 axis using 
monoclonal antibodies could affect similar anti-tumour immune responses in mice with 
established tumours.16 The secretion of inflammatory cytokines by infiltrating 
lymphocytes, for example interferon gamma, leads to the up-regulation of PD-L1 on 
the tumour cell surface and surrounding tissues, resulting in the inhibition of T cell 
activity as a result of PD-1/PD-L1 interaction resulting in tumour immune evasion, a 
process referred to as ‘adaptive immune resistance’.17 
 
Numerous trials of anti-PD-1 and anti-PD-L1 therapies have demonstrated impressive 
clinical responses with survival benefit in a variety of solid18-32 and haematological 
cancers33,34, transforming the outlook for a large number of patients. Currently, 
nivolumab and pembrolizumab, both monoclonal antibodies to PD-1, are licensed by 
the FDA for use in advanced melanoma, metastatic non-small cell lung cancer, 
metastatic squamous cell head and neck cancers and Hodgkin lymphoma (Table 1).  
 
The success of both anti-PD-1 and anti-CTLA-4 therapy has paved the way for the 
clinical development of a large number of immunomodulatory antibodies, creating 
much excitement in the field of cancer immunotherapy. However, an important 
question regarding the precise nature of the antigens that are recognised by heavily 
regulated lymphocytes remains to be fully answered. 
 
 
 
 
 
FDA approved checkpoint molecule antibodies 
Nivolumab (PD-1) Metastatic melanoma24 
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Table 1: Current FDA approved checkpoint molecule inhibitors and clinical trial 
references. 
 
Characterisation of antigens recognised by tumour infiltrating lymphocytes  
 
Tumour antigens have typically been classified into two main categories based on their 
distribution within tissues. Tumour-associated antigens (TAAs) include tissue 
differentiation markers (e.g MART-1, gp100, TRP-1 and TRP-2 proteins) expressed 
both on normal tissue and tumour cells and cancer-testes antigens (e.g NY-ESO-1 and 
MAGE-A3) expressed in germ cells and tumour cells (for review please refer to 
Kawakami et al 2004).36 In contrast, mutations that are found exclusively within cancer 
cells that are not present in normal tissue give rise to tumour specific antigens often 
referred to as tumour neoantigens. 
 
In 1991, work carried out Van Der Bruggen et al revealed the presence of a gene 
encoding the antigen MAGE-1, found within melanoma cells and not in most normal 
tissues, recognised by cytotoxic lymphocytes in a patient with melanoma.37 This gave 
rise to the concept of tumour-associated antigens, following which the discovery of 
several other key self-antigens encoded by gp100, MART-1 and tyrosinase 
occurred.38-40 The identification of tumour-associated antigens, particularly the finding 
that these were often shared between patients, drew much attention in the field of 
Metastatic NSCLC27 
Hodgkin lymphoma33 
Metastatic RCC19 
Metastatic squamous cell carcinoma of the head and neck23 
Locally advanced or metastatic urothelial carcinoma28 
Pembrolizumab (PD-1) Metastatic melanoma25 
Metastatic NSCLC29 
Metastatic squamous cell carcinoma of the head and neck30 
Hodgkin lymphoma34 
Atezolizumab (PD-L1) Locally advanced or metastatic urothelial carcinoma31 
Metastatic NSCLC26,32 
Ipilimumab (CTLA-4) Metastatic melanoma35 
Ipilimumab and Nivolumab 
(PD-1 and CTLA-4) 
Metastatic melanoma18 
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cancer immunology leading to the development of adoptive cellular therapies and 
cancer vaccines targeted against TAAs.  
 
Several groups including those of Thierry Boon and Hans Schreiber have 
demonstrated the role of tumour neoantigens in promoting effective anti-tumour 
immunity. The mutagenisation of a mouse tumour cell line (P815 tumour cell line) led 
to a highly immunogenic tumour cell variant that was rejected by syngeneic mice due 
to the expression of novel mutated antigens, resulting in a cytotoxic anti-tumoural 
immune response.41 A subsequent study showed the presence of a CD8+ T 
lymphocyte response to a peptide arising from a tumour-specific somatic mutation in 
the coding region of a nucleic acid helicase, p68, in an ultraviolet light-induced murine 
tumour.42 In a separate study, CD4+ T lymphocytes were shown to recognise unique 
tumour neoantigens expressed exclusively within the tumour cells of an ultraviolet-light 
induced murine model of cancer.43  
 
These studies were bridged to human data by the demonstration of tumour infiltrating 
lymphocytes capable of recognising a tumour neoantigen encoded by mutated cyclin-
dependent kinase 4 (CDK4) in a human melanoma specimen44, and of others capable 
of recognising antigen arising from a mutated beta-catenin gene exclusively found 
within melanoma cells45. A separate study showed the presence of cytotoxic 
lymphocytes specific to a neoantigen arising from mutated CASP-8 in a squamous cell 
carcinoma of the oral cavity.46 These findings provided initial support that, in humans, 
tumour specific T cells, which we refer to as neoantigen reactive T cells (NARTs), have 
the capacity to recognise neoantigens found exclusively within the tumour. 
 
Taken together, data from these studies support the concept of anti-tumoural immune 
responses against antigens that are expressed as a consequence of the accumulation 
of mutations within tumours. One can also infer from these studies that the level of 
tumoural mutational burden may confer a survival advantage through the expression 
of neoantigens that are recognised by the immune system, driving a specific anti-
tumoural immune response. Given that neoantigens are found to occur as a result of 
mutations that are largely ‘private’ and unique to individual tumours, the therapeutic 
targeting of neoantigens represented a huge translational challenge during the 1990s, 
in an era where next generation sequencing was not as economical and readily 
available as it is today, halting the development of personalised medicine. This led to 
a shift in the focus of cancer immunology research towards tumour antigens that were 
 6 
shared between tumours of different patients across varied tumour types, leading to 
increasing focus on TAAs. 
 
The renaissance of tumour neoantigens in cancer immunology 
 
The renaissance of neoantigens has been facilitated by improvements in next 
generation sequencing techniques and bioinformatics pipelines, including the 
development of neoantigen peptide prediction algorithms, on a background of 
disappointing results from immunotherapeutic strategies targeted against TAAs. 
 
In the last fifteen years, a number of studies have pointed towards the importance of 
neoantigen-directed immune responses. In one study, T cell responses towards 
neoantigens arising from five tumour-specific mutations were shown to predominate 
over those against tumour-associated antigens within the same patient.47 A separate 
study showed the presence of neoantigen reactive CD4+ cells in the tumours of 
patients with melanoma.48 Importantly, neoantigen specific T cells have also been 
detected in the peripheral blood of patients with melanoma.49 Taken together, data 
from these studies support the role of neoantigens in anti-tumour immunity; however 
further studies directly comparing the relative contributions of neoantigens versus 
tumour-associated antigens in the anti-tumoural immune response are necessary. 
 
Further work in murine models supported the development of personalised 
immunotherapies for patients with cancer. Next generation sequencing and MHC 
Class I in silico prediction methods were used to identify tumour specific mutations and 
corresponding predicted peptides in a murine model of MCA-induced fibrosarcoma. A 
predicted neoantigen arising from mutated spectrin beta-2 was subsequently 
demonstrated to be a key mediator of the anti-tumoural T cell response. Furthermore, 
the authors reported that the immunological editing of the cancers in these mice 
occurred as a result of a selection process dependent on T cells.50 The concept of the 
immunological editing of cancers relates to earlier work carried out by the same 
authors51 and comprises of three key components (for review see Dunn et al 2002).52 
This includes the elimination of tumours through cancer immunosurveillance, 
maintenance of cancer in an equilibrium state as a result of the endogenous immune 
response and lastly, tumour escape. Tumours may evade immune-mediated 
destruction as a result of the clonal evolution of cancerous cells with preferential 
expansion of tumoural subclones lacking immunogenicity or those with the ability to 
suppress immune responses leading to tumour progression.  
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In a separate study, next generation sequencing was employed to identify tumour 
specific non-synonymous mutations in melanoma cells derived from a B16F10 mouse 
model. Importantly, in mice harbouring tumours, immunisation with peptides encoded 
for by non-synonymous mutations predicted to bind to MHC Class I molecules by in 
silico prediction algorithms lead to tumour control.53 The importance of MHC Class II 
presented neoantigens and tumour-reactive CD4+ cells has also been reported.54 In 
this study, Kreiter et al proposed a bioinformatics method through which poly-neo-
epitope mRNA vaccines could be synthesised based on both MHC Class II predicted 
binding and expression levels of tumour mutations. They successfully demonstrated 
that such approaches used to generate vaccines targeted against CD4+ neoantigens 
resulted in a potent anti-tumour effect in three separate murine models of cancer. 
Interestingly, through use of the same bioinformatic prediction algorithm, a large 
number of mutations giving rise to neoantigens predicted to bind to MHC Class II in 
human cancers were also found.  
 
Previous pre-clinical data has shown the ability of tumour-reactive CD4+ cells to 
develop cytotoxic activity leading to tumour rejection in murine B16/BL6 tumour 
models.55 Moreover, durable clinical responses to adoptively transferred NY-ESO-1 
specific or tumour neoantigen specific CD4+ cells were reported in metastatic 
melanoma56 and cholangiocarcinoma57 respectively. Together, these studies provide 
support for the role of CD4+ effector cells in the adaptive anti-tumoural immune 
response. This may be achieved through either direct cytotoxic activity in the context 
of MHC class II expressing tumours and/or facilitation of CD8+ T cell expansion and 
effector function to promote immune-mediated tumour cell destruction. 
 
The studies discussed above provide insight into the successful application of next 
generation sequencing techniques and neoantigen prediction algorithms to identify 
and characterise TAAs and tumour neoantigens presented by MHC Class I and Class 
II molecules. Moreover, they highlight the crucial role of CD4+ T cells in generating 
effective anti-tumoural immune responses and underline the importance of further 
research in this area, particularly for the development of CD4+ targeted 
immunotherapeutic strategies for patients with cancer. 
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The interplay between neoantigen reactive T cells and the response to cancer 
immunotherapy 
 
Several groups have demonstrated the presence of neoantigen driven T cell 
responses in human cancers responding to either adoptive cellular therapy and/or 
immunomodulatory antibodies. The persistence of neoantigen specific T cell clones 
recognising mutated growth arrested-specific gene 7 (GAS7) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) in the peripheral blood of a patient with stage IV 
melanoma reported to have a complete response after adoptive transfer of autologous 
tumour infiltrating lymphocytes was inferred to be indicative of their role in maintaining 
a clinical response.58 Moreover, neoantigen reactivity of adoptively transferred T cells 
was elucidated in three patients with advanced melanoma with objective responses to 
adoptive cellular therapy59, and neoantigen reactive CD4+ T cells were identified in a 
patient with metastatic cholangiocarcinoma displaying a response to adoptive cellular 
therapy.57 Furthermore, neoantigen reactive CD8+ T cell responses were also reported 
in a patient with advanced melanoma responsive to anti-CTLA-4 therapy.60 These 
clinical data provide evidence for the role of CD8+ and CD4+ T cells in recognising 
tumour neoantigens and suggest that immunomodulatory antibodies may act by 
enhancing the activity of neoantigen reactive T cells to achieve tumour control. 
 
Several studies over the last few years have highlighted the close interplay that exists 
between the genomic landscape of tumours and the clinical response to checkpoint 
blockade. Patients with tumours of a relatively high mutational load were found to have 
a favourable clinical outcome following anti-CTLA-4 therapy.61 Similarly, patients with 
metastatic melanoma categorised as deriving clinical benefit from anti-CTLA-4 therapy 
were found to have a significantly higher tumour and mutational load compared to 
those patients with minimal or no clinical benefit from the drug.62 Moreover, in patients 
with NSCLC treated with anti-PD-1 therapy, a higher non-synonymous mutational load 
and neoantigen burden was associated with durable clinical responses and 
progression free survival. Furthermore, neoantigen-specific CD8+ T cell responses and 
tumour regression were seen concurrently in a responding patient.63  
 
Taken together, data from these studies highlight the intricate relationship that exists 
between the tumour mutational and neoantigen landscape and the anti-tumoural 
immune response. Furthermore, they shed light on the mechanistic activity of 
immunomodulatory antibodies, illustrating how anti-CTLA-4 and anti-PD-1 therapy 
may be used to counteract the immune regulation of neoantigen reactive T cells. It is 
 9 
important to note however, that the relationship between tumour mutational load and 
response to checkpoint blockade is not absolute; metastatic clear cell renal carcinoma 
has a moderate tumoural mutational load and is associated with durable responses to 
anti-PD-1 therapy.19,64 Moreover, colorectal cancer is not typically considered to be a 
cancer with a high mutational load64 however clinical benefit from anti-PD-1 therapy is 
reported in a subgroup of these patients.65 Patients with DNA mismatch repair 
deficiency (MMR) were shown to have an increased clinical response to anti-PD-1 
therapy likely related to an increased mutational and neoantigen load arising from 
MMR deficiency in these patients.65  
 
Intratumoural heterogeneity and anti-tumour immunity 
 
The concept of genetic intratumoural heterogeneity is well documented in a variety of 
solid and haematological cancers.66-71 Non-synonymous mutations present in every 
tumour cell give rise to clonal neoantigens that occur early in tumour evolution and are 
therefore ubiquitously expressed within tumour tissues. In contrast, subclonal or 
‘branch’ mutations resulting in the expression of subclonal neoantigens occur later, 
and so are localised to specific tumour cell subsets. 
 
The impact of intratumoural neoantigen heterogeneity on the anti-tumour immune 
response has been investigated more recently. A strong relationship between the level 
of clonal neoantigen burden and overall survival was found in patients with lung 
adenocarcinoma from analysis of sequencing data within The Cancer Genome Atlas 
(TCGA) database. More in-depth analysis revealed the upregulation of immune-
related genes including CD8, granzyme, IFNγ, PD-1, LAG-3, PD-L1 and PD-L2, in 
patients with a high burden of clonal neoantigens and a relatively low fraction of 
subclonal neoantigens, indicative of an active anti-tumour immune response within the 
tumour tissues of these patients. Of note, CD8+ T cell responses to neoantigens were 
detected in two patients with early stage NSCLC with a comparable number of 
predicted neoantigens but markedly different levels of intratumoural neoantigen 
heterogeneity. Neoantigen reactive T cells identified by MHC-multimer analysis were 
found to have increased levels of PD-1 and LAG-3 expression on their cell surface 
indicative of immune regulation of these cells.72 
 
Analysis of genomic sequencing data from anti-PD-163 or anti-CTLA-461 treated 
cohorts indicated that a high predicted clonal neoantigen burden and low neoantigen 
heterogeneity in NSCLC and metastatic melanoma was associated with favourable 
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clinical outcomes.72 This study highlights fundamental differences in the effectiveness 
of the anti-tumoural immune response driven by clonal versus subclonal neoantigens. 
A recent study exploring the tumour neoantigen landscape in matched NSCLC tumour 
specimens pre and post anti-PD-1 or dual anti-PD-1/anti-CTLA-4 therapy 
demonstrated genomic and immune-mediated loss of tumour neoantigens in resistant 
tumours.73 Moreover, immunotherapy resistance has been shown to correlate with 
tumour aneuploidy; patients with increased tumoural somatic copy number alterations 
were found to have reduced survival following anti-CTLA-4 therapy compared to those 
with reduced tumour aneuploidy.74 A lack of cytotoxic immune infiltration in tumours 
with high levels of tumour aneuploidy may contribute to the reduced survival observed 
in these anti-CTLA-4 treated patients.  
 
The studies discussed above provide insight into firstly, the importance of clonal 
neoantigens in predicting response to checkpoint blockade and secondly, the potential 
impact of checkpoint blockade and/or tumour aneuploidy in the immunological editing 
of neoantigens that may in fact lead to tumour immune evasion. Therapeutically 
targeting a wide repertoire of clonal neoantigens may theoretically provide an effective 
method of targeting the cancer mutanome although this is yet to be proven (Figure 2). 
 
T cell receptor (TCR) repertoire and clonality in cancer 
 
The repertoire of antigen specific T cells is generated in the thymus during the process 
of T cell differentiation as a result of somatic recombination of both alpha and beta 
chains of the T cell receptor, followed by central deletional tolerance of the most highly 
self-reactive T cells. The somatic rearrangement of either V and J segments or V, D, 
J segments of alpha and beta chains respectively, gives rise to the highly variable 
complementarity determining region 3 (CDR3) of the TCR, key in determining the 
antigen specificity of individual T cell clones.  
 
The level of mutational burden and genomic heterogeneity demonstrated in a variety 
of solid cancers could be reflected in the clonality and repertoire of tumour-reactive 
lymphocytes found within the tumour microenvironment, but data is currently limited. 
Tumours with a high mutational load and resulting neoantigen burden may give rise to 
a more diverse intra-tumoural T cell repertoire due to the large number of antigens 
presented to the immune system. In line with this, an association between T cell 
diversity and mutational load has previously been reported through the analysis of re-
constructed CDR3 regions from RNAseq data of samples within the TCGA database.75  
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Previous studies examining the effects of anti-CTLA-4 therapy on the TCR repertoire 
have shown peripheral blood TCR repertoire diversification following therapy76 and 
improved overall survival in patients who maintained highly abundant TCR clones 
present in the blood prior to commencement of anti-CTLA-4 therapy77. Anti-CTLA-4 
therapy has also been described to significantly increase the number of newly detected 
CD8+ melanoma specific T cell clones.78  
 
The response to anti-PD-1 therapy in metastatic melanoma has previously been 
associated with a more clonal and less diverse intratumoural TCR repertoire at 
baseline in melanoma specimens. Furthermore, in responding patients, a significant 
increase in the number of expanded TCR clones following anti-PD-1 therapy was 
reported, indicative of an enhanced oligoclonal T cell response within tumours of 
patients with metastatic melanoma.79  
 
Heterogeneity in the repertoire of T cells infiltrating different regions of clear cell renal 
carcinomas has been demonstrated using multi-region TCR sequencing80, and spatial 
heterogeneity of TILs infiltrating oesophageal cancers is also documented.81 
Interestingly, in the latter study, deeper analysis limited to the 100 most abundant TCR 
clones revealed a high degree of overlapping TCRs between tumour regions within 
each individual patient.81 Theoretically these TCR clones, present across multiple 
regions of the tumour may expand in response to common antigens found in all tumour 
regions, although the specificity of tumoural clones seen across multiple regions of a 
tumour remains to be elucidated. 
 
 
 
 
 
 
 
 
Therapeutic approaches to target the cancer mutanome and future perspectives 
 
Vaccination strategies, adoptive cellular therapies or the adoptive transfer of 
engineered T cells targeting tumour neoantigens, in conjunction with checkpoint 
molecule antibodies, represent some of the key avenues for targeting the cancer 
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mutanome that are currently being explored in a number of clinical trials. Clinical trials 
of personalised neoantigen vaccines +/- checkpoint blockade are recruiting in a variety 
of solid cancers (Table 2). Early phase trials of neoantigen based adoptive cellular 
therapies and trials of engineered T cells harbouring TCRs against neoantigens are 
eagerly awaited. 
 
 
 
Table 2: Clinical trials of neoantigen targeted immunotherapy currently open to 
recruitment.82 
 
As we move closer to achieving our goal of delivering personalised medicine for many 
of our patients, we must be thorough in our approach. It is clear, that such bespoke 
approaches to target cancers will involve sequencing and identification of tumour-
specific mutations, in silico prediction of resulting neoantigen sequences according to 
individual patient HLA types and predicted strength of neoantigen peptide binding to 
MHC to guide appropriate selection of neoantigen peptide sequences. Moreover, 
neoantigen targeted adoptive cellular therapies will rely upon information generated 
from in vitro assays testing the reactivity of tumour infiltrating lymphocytes stimulated 
with synthesised peptides. It is critical that we recognise that despite the advances in 
next generation sequencing and bioinformatics methods, these techniques are 
themselves imperfect; the limitations of neoantigen prediction algorithms and 
verification of whether tumour cells actually express such predicted neoantigens poses 
a significant challenge. The therapeutic targeting of neoantigens may minimise the 
risks of toxicities in cancer patients undergoing checkpoint blockade83, since these are 
often related to immune responses to tumour associated self antigens which may also 
Clinical trials of neoantigen targeted immunotherapies 
Trial name ClinicalTrials.gov number 
A Personalised Cancer Vaccine (NEO-PV-01) with Nivolumab for 
Patients With Melanoma, Lung Cancer or Bladder Cancer 
NCT02897765 
A Phase I Study With a Personalised NeoAntigen Cancer Vaccine in 
Melanoma 
NCT01970358 
A Phase I Personalised NeoAntigen Cancer Vaccine With 
Radiotherapy for Patients With MGMT Unmethylated, Newly 
Diagnosed Glioblastoma 
NCT02287428 
Neoepitope-based Personalised Vaccine Approach in Patients With 
Newly Diagnosed Glioblastoma 
NCT02510950 
 13 
be expressed in some normal tissues. Nevertheless, the possibility that T cell receptors 
may show some degree of cross-reactivity with unrelated self-antigens may still exist.  
 
In the context of neoantigen-targeted vaccine therapy, the expansion of regulatory T 
cells following vaccination is a likely possibility, thus combination of vaccines with 
therapeutic agents that either deplete regulatory T cells or limit the action of inhibitory 
cytokines e.g. indoleamine 2,3-dioxygenase (IDO), transforming growth factor beta 
(TGF-β) or interleukin 10 (IL-10) may be required to achieve successful clinical 
outcomes. The effectiveness of clonal neoantigen targeted adoptive cellular therapies 
will rely on infiltration of transferred T cells into the tumour microenvironment and the 
use of appropriate combinational strategies to overcome the immune regulation of 
these cells. The possibility exists that tumour immune escape may occur as a result of 
tumour resistance to IFN-γ signalling, as described previously in the context of 
acquired resistance to anti-PD-1 therapy.84 Successful therapeutic strategies of how 
best to overcome tumour resistance in this context remain to be elucidated. Despite 
these challenges, however, there is hope for optimism that we may finally have found 
an exploitable Achilles heel in our battle against cancer. 
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The birth of cancer 
immunotherapy
William Coley described 
tumour regression in 
patients with bone and 
soft tissue sarcomas 
harbouring acute bacterial 
infections.1
Discovery of CTLA-4 
CTLA-4 gene cloned and CTLA-4 
reported as a new member of 
the immunoglobulin 
superfamily.2
Discovery of tumour 
neoantigens
Report of tumour 
neoantigens in a mutagenised
mouse tumour cell line, 
capable of generating a 
cytotoxic anti-tumoural
immune response.41
Discovery of tumour
associated antigens
Discovery of the first tumour 
associated antigen encoded by 
the MAGE-1 gene.37
Discovery of PD-1
PD-1 gene cloned and role 
in classical programmed 
cell death reported.14
Anti-tumour effect of 
anti-CTLA-4
The regression of tumours in 
murine models of cancer using 
antibodies to CTLA-4 first 
described.5 
Anti-tumour effect of PD-
1/PD-L1 axis inhibition
First demonstration of 
tumour growth suppression 
in PD-L1+ murine models of 
cancer through therapeutic 
blockade of the PD-1/PD-L1 
axis using anti-PD-L1.16
FDA approval of 
ipilimumab, nivolumab
and pembrolizumab
Ipilimumab, advanced 
melanoma. Pembrolizumab
& Nivolumab advanced 
melanoma, NSCLC, Hodgkin 
lymphoma and renal cell 
cancer.
Genetic determinants of 
response to checkpoint 
blockade
Several studies demonstrate 
the importance of tumour 
mutational load and 
neoantigen burden in response 
to checkpoint blockade.61-63, 72
Immunotherapeutic targeting of cancer’s Achilles heel
Subclonal neoantigen
targeted therapy 
Clonal neoantigen
targeted therapy Multi-peptide vaccine or 
adoptive cellular therapy 
targeting subclonal or clonal 
neoantigens
Tumour cells (patterned circles) 
comprising of two types of 
neoantigens: clonal (blue) and 
subclonal neoantigens
(accompanying colour)
Tumour neoantigen landscape 
following subclonal or clonal 
neoantigen targeted 
immunotherapy. Grey circles 
indicative of eliminated tumour
clones
